摘要
目的探讨和血明目片联合羟苯磺酸钙治疗早期糖尿病视网膜病变(DR)的临床疗效,以及对患者眼部动脉血流动力学和眼底出血的影响。方法选取崇州市人民院2016年3月至2018年12月收治的早期DR患者256例,按随机数字表法分为对照组和观察组,各128例。两组患者均予常规治疗,并予羟苯磺酸钙胶囊,观察组患者加服和血明目片,两组均治疗3个月。结果观察组总有效率为88.28%,显著高于对照组的70.31%(P<0.05);与治疗前比较,两组患者治疗后的黄斑厚度、血管瘤体积、出血斑面积和阻力指数(RI)均显著减小,视野灰度值和血液黏度均显著降低,观察组患者上述指标改善程度均显著优于对照组(P<0.05);观察组与对照组不良反应发生率相当(2.34%比3.12%,χ^2=0.147,P=0.702>0.05)。结论和血明目片联合羟苯磺酸钙治疗早期DR疗效确切,能明显改善患者的眼底症状和眼部血流动力学指标。
Objective To investigate the effect of Hexuemingmu Tablets combined with calcium dobesilate on early diabetic retinopathy(DR)and its influence on ophthalmic artery hemodynamics and fundus hemorrhage.Methods A total of 256 early DR patients admitted to Chongzhou People’s Hospital from March 2016 to December 2018 were selected and divided into the control group and observation group according to random number table method,128 cases in each group.Both groupsreceived conventional treatment and was given calcium dobesilate,while the observation group was added with Hexuemingmu Tablet.Both groups were treated for 3 months.Results The total effective rate was 88.28%in the observation group,which was significantly higher than 70.31%in the control group(P<0.05).Compared with before treatment,the macular thickness,hemangioma volume,bleeding spot area andresistance index(RI),the visual field gray valueand blood viscosity of central retinal artery of the two groups were significantly reduced,and the above indexes in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was equivalent to that in the control group(2.34%vs.3.12%,χ^2=0.147,P=0.702>0.05).Conclusion The combination of Hexuemingmu Tabletscombined with calcium dobesilate has definite curative effect on DR,which can improve fundus symptoms and ocular hemodynamics.
作者
高立
祁涛
许文彬
万灵
GAO Li;QI Tao;XU Wenbin;WAN Ling(Department of Otolaryngology,Chongzhou People's Hospital,Chengdu,Sichuan,China 611230;Department of Ophthalmology,Sichuan Provincial People's Hospital,Chengdu,Sichuan,China 610072)
出处
《中国药业》
CAS
2020年第10期133-135,共3页
China Pharmaceuticals
基金
四川省科技计划项目[2016FZ0091]。
